Key Takeaways
- • Cleveland Clinic and Khosla Ventures formalized a strategic collaboration on October 14, 2025, connecting a major U.S. health system with a Silicon Valley venture firm specializing in healthcare and technology investments.
- • Khosla Ventures portfolio companies gain clinical validation access across all stages of development—from early-stage testing through commercial adoption—directly with Cleveland Clinic providers, reducing time-to-market for healthcare startups.
- • Cleveland Clinic secures a direct pipeline to emerging technologies in artificial intelligence, digital health, and next-generation therapeutics, strengthening its innovation capacity and competitive positioning.
- • The partnership leverages complementary expertise: Khosla Ventures brings venture capital networks and early-stage companies; Cleveland Clinic contributes biomedical research capabilities, clinical credibility, and provider access.
- • Hal Paz, MD, operating partner at Khosla Ventures and former health system CEO, emphasized AI as healthcare's most transformative technology, positioning the collaboration as a vehicle for scaling AI-driven healthcare innovations.
Summary
Cleveland Clinic and Khosla Ventures announced a strategic collaboration designed to accelerate innovation in healthcare by combining the health system's clinical expertise with the venture capital firm's portfolio of early-stage companies and technology investment networks. The partnership, announced on October 14, 2025, aims to address pressing challenges in healthcare delivery and create scalable solutions at the intersection of medicine and technology.
The collaboration provides a bilateral advantage structure. Khosla Ventures portfolio companies gain access to Cleveland Clinic's clinical infrastructure and provider network for testing and validating technologies across all development stages, from early clinical validation through commercial adoption. This direct clinician engagement gives startups a competitive pathway to demonstrate real-world value and accelerate scaling. For Cleveland Clinic, the partnership establishes a direct pipeline to emerging technologies, particularly in artificial intelligence, digital health, and next-generation therapeutics—areas increasingly central to healthcare transformation.
Hal Paz, MD, operating partner at Khosla Ventures and former CEO of multiple large-scale health systems, framed AI as "the most transformative technology of our lifetime" and emphasized that healthcare's disruption will be "massive." He stated the Cleveland Clinic relationship gives Khosla portfolio companies "an advantage to validate and scale their innovations." Geoff Vince, PhD, Chief of Cleveland Clinic Innovations, characterized the partnership as pairing "our health system's expertise in biomedical research, clinical care and innovation with Khosla Ventures' venture expertise and network of entrepreneurs to drive meaningful advancements in the healthcare industry."
The partnership reflects a broader institutional trend: large healthcare systems increasingly function as innovation platforms and clinical validation partners for venture-backed companies, while VCs seek clinical credibility and regulatory pathways to de-risk emerging healthcare technologies. For institutional investors monitoring healthcare innovation and digital health trends, this collaboration signals how leading health systems are positioning themselves as critical infrastructure for scaling healthcare technology from concept to clinical and commercial deployment.
The collaboration provides a bilateral advantage structure. Khosla Ventures portfolio companies gain access to Cleveland Clinic's clinical infrastructure and provider network for testing and validating technologies across all development stages, from early clinical validation through commercial adoption. This direct clinician engagement gives startups a competitive pathway to demonstrate real-world value and accelerate scaling. For Cleveland Clinic, the partnership establishes a direct pipeline to emerging technologies, particularly in artificial intelligence, digital health, and next-generation therapeutics—areas increasingly central to healthcare transformation.
Hal Paz, MD, operating partner at Khosla Ventures and former CEO of multiple large-scale health systems, framed AI as "the most transformative technology of our lifetime" and emphasized that healthcare's disruption will be "massive." He stated the Cleveland Clinic relationship gives Khosla portfolio companies "an advantage to validate and scale their innovations." Geoff Vince, PhD, Chief of Cleveland Clinic Innovations, characterized the partnership as pairing "our health system's expertise in biomedical research, clinical care and innovation with Khosla Ventures' venture expertise and network of entrepreneurs to drive meaningful advancements in the healthcare industry."
The partnership reflects a broader institutional trend: large healthcare systems increasingly function as innovation platforms and clinical validation partners for venture-backed companies, while VCs seek clinical credibility and regulatory pathways to de-risk emerging healthcare technologies. For institutional investors monitoring healthcare innovation and digital health trends, this collaboration signals how leading health systems are positioning themselves as critical infrastructure for scaling healthcare technology from concept to clinical and commercial deployment.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.